Distribution of TYMS, MTHFR, p53 and MDR1 gene polymorphisms in patients with breast cancer treated with neoadjuvant chemotherapy

被引:28
作者
Alberto Henriquez-Hernandez, Luis [1 ,3 ]
Murias-Rosales, Adolfo [2 ,3 ]
Gonzalez-Hernandez, Ana [3 ,4 ]
Cabrera de Leon, Antonio [3 ,4 ]
Diaz-Chico, Nicolas [3 ,5 ]
Fernandez-Perez, Leandro [1 ,3 ]
机构
[1] Univ Las Palmas Gran Canaria, Dept Clin Sci, Las Palmas Gran Canaria 35016, Spain
[2] Hosp Univ Insular Gran Canaria, Med Oncol Serv, Las Palmas Gran Canaria 35016, Spain
[3] ICIC, Madrid, Spain
[4] Hosp La Candelaria, Hosp Univ La Candelaria, Res Unit, Santa Cruz De Tenerife 38010, Spain
[5] Univ Las Palmas Gran Canaria, Physiol Biochem & Mol Biol Dept, Las Palmas Gran Canaria 35016, Spain
关键词
Breast cancer; Neoadjuvant chemotherapy; Toxicity; Adverse reaction; Polymorphism; MTHFR; p53; ACUTE LYMPHOBLASTIC-LEUKEMIA; METHYLENETETRAHYDROFOLATE REDUCTASE C677T; THYMIDYLATE SYNTHASE; OVARIAN-CANCER; TOXICITY; PHARMACOGENOMICS; THERAPY; RESISTANCE; VARIANTS; RISK;
D O I
10.1016/j.canep.2010.06.013
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose To investigate the role of TSER (TYMS), C677T (MTHFR), Arg72Pro (p53) and C3435T (MDR1) gene polymorphisms in breast cancer patients treated with 5-fluorouracil and cyclophosphamide-based neoadjuvant chemotherapy. Results Observed allelic frequencies were: TSER, (2) 0.54 and (3) 0.46; MTHFR C677T, (C) 0.59 and (T) 0.41; p53 Arg72Pro, (Arg) 0.73 and (Pro) 0.27; MDR1 C3435T, (C) 0.52 and (T) 0.48. MTHFR allele T and p53 allele Pro were strongly associated with toxicity due to chemotherapy (odds ratio, 7.1 (95% confidence interval, 1.4-36.1; p = 0.018) and 7.0 (95% confidence interval, 1.2-40.5; p = 0.029), respectively). Conclusion We introduced new data related to the contribution of p53 codon 72 to toxicity due to 5-fluorouracil and cyclophosphamide-based neoadjuvant chemotherapy in patients with breast cancer. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码:634 / 638
页数:5
相关论文
共 45 条
[21]   Role of the MTHFR polymorphisms in cancer risk modification and treatment [J].
Kim, Young-In .
FUTURE ONCOLOGY, 2009, 5 (04) :523-542
[22]   P53 MUTATIONS INCREASE RESISTANCE TO IONIZING-RADIATION [J].
LEE, JM ;
BERNSTEIN, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (12) :5742-5746
[23]   ATP binding cassette transporters and drug resistance in breast cancer [J].
Leonessa, F ;
Clarke, R .
ENDOCRINE-RELATED CANCER, 2003, 10 (01) :43-73
[24]   P53 STATUS AND THE EFFICACY OF CANCER-THERAPY IN-VIVO [J].
LOWE, SW ;
BODIS, S ;
MCCLATCHEY, A ;
REMINGTON, L ;
RULEY, HE ;
FISHER, DE ;
HOUSMAN, DE ;
JACKS, T .
SCIENCE, 1994, 266 (5186) :807-810
[25]   Pharmacogenomics: from bedside to clinical practice [J].
Marsh, S ;
McLeod, HL .
HUMAN MOLECULAR GENETICS, 2006, 15 :R89-R93
[26]   Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: The Scottish randomised trial in ovarian cancer [J].
Marsh, Sharon ;
Paul, Jim ;
King, Cristi R. ;
Gifford, Gillian ;
McLeod, Howard L. ;
Brown, Robert .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (29) :4528-4535
[27]   Impact of pharmacogenomics on clinical practice in oncology [J].
Marsh, Sharon .
MOLECULAR DIAGNOSIS & THERAPY, 2007, 11 (02) :79-82
[28]  
MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO
[29]  
2-6
[30]  
Nilsson G, 1999, CANCER RES, V59, P3180